pDom-MAGED4B

**pDom-MAGED4B** is a DNA vaccine that encodes the cancer-associated antigen MAGED4B and is designed to stimulate a targeted anti-tumor immune response, specifically T cell activation against MAGED4B-expressing tumor cells. The vaccine aims to enhance tumor infiltration of T cells and induce a cytotoxic response leading to tumor growth inhibition. It has been investigated preclinically in HLA-A2 transgenic mouse models where it demonstrated efficacy in delaying tumor growth, particularly in cancers engineered to express MAGED4B. The mechanism centers on induction of cellular immunity via the expression of the MAGED4B antigen, a known tumor-associated antigen, triggering immune recognition and destruction of cancer cells expressing MAGED4B. pDom-MAGED4B is typically studied either alone or as part of a combination therapy (such as with other DNA vaccines or immune checkpoint inhibitors like anti-PD-1), but this entry refers specifically to the MAGED4B-encoding component. The vaccine is primarily being developed for solid tumors, notably melanoma and other cancers with upregulated MAGED4B expression[1].

Other names

pDom-M